JP2023515974A5 - - Google Patents
Info
- Publication number
- JP2023515974A5 JP2023515974A5 JP2022551593A JP2022551593A JP2023515974A5 JP 2023515974 A5 JP2023515974 A5 JP 2023515974A5 JP 2022551593 A JP2022551593 A JP 2022551593A JP 2022551593 A JP2022551593 A JP 2022551593A JP 2023515974 A5 JP2023515974 A5 JP 2023515974A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- modified
- nucleic acid
- modified oligonucleotide
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062983555P | 2020-02-28 | 2020-02-28 | |
| US62/983,555 | 2020-02-28 | ||
| US202063085111P | 2020-09-29 | 2020-09-29 | |
| US63/085,111 | 2020-09-29 | ||
| PCT/US2021/019960 WO2021174036A1 (en) | 2020-02-28 | 2021-02-26 | Compounds and methods for modulating scn1a expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023515974A JP2023515974A (ja) | 2023-04-17 |
| JP2023515974A5 true JP2023515974A5 (enExample) | 2024-03-05 |
Family
ID=77491960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022551593A Pending JP2023515974A (ja) | 2020-02-28 | 2021-02-26 | Ｓｃｎ１ａ発現を調節するための化合物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230043648A1 (enExample) |
| EP (1) | EP4110919A4 (enExample) |
| JP (1) | JP2023515974A (enExample) |
| TW (1) | TW202140788A (enExample) |
| UY (1) | UY39104A (enExample) |
| WO (1) | WO2021174036A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY207352A (en) * | 2018-03-21 | 2025-02-21 | Regeneron Pharma | 17-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof |
| US20240360449A1 (en) * | 2021-08-27 | 2024-10-31 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating scn1a expression |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2872147T3 (da) * | 2012-07-13 | 2023-02-20 | Wave Life Sciences Ltd | Fremgangsmåde til fremstilling af kirale oligonukleotider |
| PL3484524T3 (pl) * | 2016-07-15 | 2023-03-20 | Ionis Pharmaceuticals, Inc. | Związki i sposoby modulacji smn2 |
| KR20260009385A (ko) * | 2017-08-25 | 2026-01-19 | 스톡 테라퓨틱스, 인크. | 병태 및 질환 치료용 안티센스 올리고머 |
| US10765760B2 (en) * | 2018-05-29 | 2020-09-08 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| CA3110211A1 (en) * | 2018-08-20 | 2020-02-27 | Rogcon, Inc. | Antisense oligonucleotides targeting scn2a for the treatment of scn1a encephalopathies |
| KR20220113743A (ko) * | 2019-12-06 | 2022-08-16 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 안티센스 올리고머 |
-
2021
- 2021-02-26 JP JP2022551593A patent/JP2023515974A/ja active Pending
- 2021-02-26 EP EP21760424.8A patent/EP4110919A4/en active Pending
- 2021-02-26 WO PCT/US2021/019960 patent/WO2021174036A1/en not_active Ceased
- 2021-02-26 US US17/802,324 patent/US20230043648A1/en active Pending
- 2021-02-26 TW TW110107122A patent/TW202140788A/zh unknown
- 2021-03-01 UY UY0001039104A patent/UY39104A/es not_active Application Discontinuation